The DCTN5 antibody targets the dynactin subunit 5 (DCTN5), a critical component of the dynactin complex, which regulates cytoplasmic dynein-driven microtubule-based intracellular transport. Dynactin, a multi-subunit protein complex, enhances dynein's processivity and facilitates interactions with cargoes, organelles (e.g., mitochondria, lysosomes), and the cell cortex. DCTN5. also known as p25. contributes to dynactin structural integrity by stabilizing interactions between other subunits, such as p150^Glued (DCTN1) and actin-related proteins (Arp1). Dysregulation of dynactin or dynein is implicated in neurodegenerative diseases (e.g., ALS, Perry syndrome) and developmental disorders. DCTN5 antibodies are widely used in research to investigate dynactin assembly, retrograde transport mechanisms, and pathological defects. They enable detection via techniques like Western blotting, immunofluorescence, and immunoprecipitation, aiding studies on neuronal health, mitotic spindle positioning, and viral trafficking. Commercial DCTN5 antibodies are typically validated in model systems (e.g., human, mouse), with specificity confirmed through knockout controls. Recent studies highlight DCTN5's role in ciliogenesis and autophagy, expanding its relevance beyond conventional transport paradigms.